Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 2.20 167,746 08:00:00
Bid Price Offer Price High Price Low Price Open Price
2.10 2.30 2.20 2.20 2.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.19 8
Last Trade Time Trade Type Trade Size Trade Price Currency
15:28:54 O 37,500 2.10 GBX

Hemogenyx Pharmaceuticals (HEMO) Latest News

More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Share Charts

1 Year Hemogenyx Pharmaceuticals Chart

1 Year Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

1 Month Hemogenyx Pharmaceuticals Chart

Intraday Hemogenyx Pharmaceuticals Chart

Intraday Hemogenyx Pharmaceuticals Chart

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
04/10/201900:00Hemogenyx Pharmaceuticals212
13/9/201913:29HEMOGENYX 2018/19 Moderated3,454
06/11/201807:57Hemogenyx Blockbuster IP licencing to Big Pharma43

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 2.20p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 2.10p and a 12 week average price of 2.10p.
The 1 year high share price is 4.28p while the 1 year low share price is currently 1.95p.
There are currently 356,042,854 shares in issue and the average daily traded volume is 431,016 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £7,832,942.79.
davevt: So, why is the share price down here? Why does the Dr feel the need to do leaky tweets to ramp his share price. Why does he out of the blue announce revenues are going into subsidiaries which he is the sole director of, and not into the coffers of the company you're invested in, and doesn't tell you this in advance, only when the news is released? Why has the company not even completed successful in Vivo trials? Why does the company release meaningless patent applications as 'news' when they are part of the usual course of business, but instead does it to try and ramp prices. Go on John..chop chop 😂
badger60: Poor davevd.. delusional as usual. Funny how his " gift" deserts him when the share price spikes in the opposite direction.... When he posted this on 29th May the share price was languishing in the low 2's........the VERY NEXT DAY it peaked at 4.3p on record trading volumes !!! got that so wrong...and it made you look very must be a gift... davevt - 29 May 2019 - 08:51:39 - 1594 of 1850HEMOGENYX 2018/19 Moderated - HEMO 2.1, how long till it's in the 1s? It's OK, badger will say it's 'cheap' and John will still be crying.. Fwiw, I've recently added appx 1mio shares at circa average of 3pps....
bc4: Let me put it in to perspective on the 10th of June HEMO share price was about 2.5p it is now 3.15p so take no notice of the muppet
the abbot: Hi All, been a busy weekend but have received an email response from Hemo regarding a few questions I had surrounding the Broker. Before giving the detail I would like to say how pleased I was that I received a response, quite often companies seem ignorant towards investors concerns and place themselves above PI’s who, without which many of these companies would struggle to get of the starting blocks, therefore it is appreciative to be recognised for our support, thus I am happy to say I had a pretty speedy response. As we know, Hemo share our own disappointment with the share price and although they recognise it is it is largely outside of their control, whilst they focus on the research, they have given reason for the choice of Broker and hinted at potential broker plans moving forward. SP Angel is considered a specialist broker in the healthcare and biotechnology sector and brings with it many of the benefits and contacts that would be expected for one that understands the sector, thus the selection, This cross sector experience seems to be the main factor behind the choice. I was particularly interested in my questions as to the marketing and sharing of research notes and although, as with many institutional brokers, research notes are primarily written and for the sole use of institutional buyers (PI’s often do not get to assess from a professional angle the investment case, i.e. we do our own research) however, I believe that share price Angel are considering whether a research note could be beneficial, I certainly get the impression the Company expect the price to increase and trading patterns to stabilise as they hit more significant milestones such as clinical trials. I was also informed that share price angel does get involved in the Vox Markets podcasts so we should look out for these and of course we know that the news announcements are picked up by Proactive Investors. All in all I get the impression that Hemo are as frustrated as us but their concentration is the research which to be honest is going great guns, they know clinical trials will be a significant milestone and with a broker that can draw upon sector contacts, I get the feeling we will not have to long to wait for things to change.
pwhite73: dave4545 - "Killing the market and full time deramper vultures like pwhite clean up" Wrong never shorted a share in my life and PIs generally cannot short AIM and micro-cap stocks only institutions can. What I have learned over the years is do not hold AIM/micro-cap stocks long term. If you do you will pay the price with diluted placings, warrants, options, conversion loans, death spiral financing and eventually suspension and cancellation. You trade these stocks on a daily or weekly basis. I have a particular interest in bio-pharma stocks because these are the ones that can really motor if the markets believe their story. I check the ADVFN 'Toplists' daily to look at the biggest percentage risers and fallers. I normally base my trades around these. Hemo came onto my radar again as it was a big riser for 30/05/2019. I had previously noted that Hemo could never seem to hold onto any gains, that is when I really started taking a look at the company. The cracks and fissures that are in PYC and ERX can be found in Hemo. It doesn't really have anything to re-rate it. True to form Hemo share price has collapsed again. But it will rise again on the next positive RNS and fall again as day traders pile in and out whilst the market professionals short the stock.
pwhite73: badger60 - "but the enterprise value of Hemogenyx is worth far more than the current share price." Says who? Twice in its short public history opportunities arose to re-rate. Firstly when back in November 2017 news was leaked to the Mail on Sunday about a collaboration with Oxford University. The share price tripled overnight only to slump back when Dr Sandler explained in an RNS what the collaboration consisted of. Secondly in February 2019 this year when news leaked again (wink wink nudge nudge) of the development of a humanised mouse. Dr Sandler issued an RNS to clarify the development and once again the share price slumped back. At every attempt to explain to the markets what they do and the progress they've made the share price collapses. Thursday, Friday of this week followed in similar vein. This is why with confidence I can categorically state this company will never re-rate. I don't know how long you've been investing but you may wish to look up the history of a company called EIRX Theurapeutics (ERX) another biotech resting its hopes on humanised mouse technology to beat cancer. The markets will not buy into it.
badger60: PWhite73 I beg to differ with your emphatic last paragraph in as much as I think that the Hemogenyx share price will start to reflect real potential that is embedded in the products that are being actively developed.....which is many times 2.8pps. The current market cap of circa 10mio is a complete nonsense, especially when compared to failed companies like IMM which peaked at 250mio+ on hype.....before Lupuzor failed abysmally at phase3 by the FDA.....and the same can also be said for Motif. IMO, Dr.Sandler's approach has been far more circumspect and he is now in the eviable position of being contractually supported by a first class and convertible loan committed partner on 2 potentially groundbreaking products through to commercialisation. Even more importantly is the recent CDX update and his interview with Zac Mir about the probable anticipated CDX contract, on which I've already posted. Nothing written in stone here, unlike the way that you tediously express yourself on stock bbs, but the enterprise value of Hemogenyx is worth far more than the current share price. Many thanks for all your "after the event"'s such pity that you struggle to have an original thought of your own. Perhaps one of these days you may even summon up the courage to buy some shares.......but ask your mum first before you do......
pwhite73: Couple of other things. Only 27% of the company's shares are in free float. 73% are held by directors and institutions. Some PIs think the less shares available the more they are sought after a bit like gold nuggets. It doesn't necessarily work like that. The less shares available the wider the spread and the more illiquid the stock can be. The shares ended up 25% on the week but there were no trades on 28/05/2019 and the 29/05/2019. Had it not been for the news on 30/05/2019 I doubt a single share would have traded on all week. The previous week only 19 shares were traded all week!!. If you want a real comparison with Hemo then don't look at OBD look at PYC. Another biotech company developing software to assist in the detection and elimination of cancer. The company has been listed since 2004 and within the last 15 years the share price has done nothing. Its had its peaks like Hemo but has always returned to its base of 2p - 3p range. In Nov 2017 the share price went from 1p to 34P in a matter of three days as PIs misinterpreted an RNS. PYC had to correct the markets and the price plunged back to base. Hemo's problems are identical to PYC's. PYC has an impeccable list of employees, Professors and doctors. It has a who's who list of partnerships including Eli Lily and Merck. It has won prestigious awards and received government grants at the national and European level. It has had its research, findings and technology published in medical journals. But like Hemo there is no definite evidence to suggest its technology facilitates the elimination of cancer. PYC listed at 2p on 20/12/2004. Fifteen years on the share price is at 3p. There is something else you need to understand. A lot of these so called biotech companies are little more than research laboratories of universities masquerading as Plcs to raise finance on capital markets. This is the case with PYC and Hemo. PYC is really an off shoot laboratory of Oxford University and Hemo is really an off shoot laboratory of State of New York Medical Centre. Both companies share the same address as their respective universities. If you think the markets are suddenly going wake up to the potential of Hemo and re-rate the stock you are wrong big time. Hemo listed on 05/10/2017 at 3.5p . Two years on the share price is at 2.80p
asat91: Well yes at the moment only the subsidiaries have a valuation. The valuations aren't plucked out of thin air, they are based on money invested in the companies. So that's why the 2 subsidiaries have a specific current value of $8mill and $12mill. CDX antibodies is a potential therapy product that has potential revenues in the future after it has gone through clinical trials, but it has no current value. I'm not saying that it is useless or that the product won't be successful! I'm simply saying that you cannot put a specific value on CDX antibodies product at the moment. Since the valuation of the 2 subsidiaries is double the current market cap of the parent company, the HEMO share price should be about 5p at the moment + maybe a little bit for potential CDX value which will increase with every deal/clinical trial the product goes through.
tullynessle: I don't believe it was the tweet. Hemogenyx were speaking recently at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), at Trinity College, Oxford. Is it possible that their presentation updated/influenced the conference audience? More details in the posts dated 3 Sept and copied below. Tullynessle 3 Sep '18 - 20:31 - 494 of 539 Edit 0 0 0 Of the thirty one (31) confirmed speakers at the "From Laboratory to Clinic: Accelerating Experimental Medicine Approaches" conference (Sept 4 thru Sept 7), - 28 speakers represent international Universities & Medical/Research Institutes - 1 speaker represents SomaLogic [] - 1 speaker represents Genentech a Member of the Roche Group [] - 1 speaker represents HemoGenyx [] I suspect that all is well earned recognition for Dr Vladislav Sandler Ph.D. and the Hemogenyx team. Extract: CONFIRMED SPEAKERS *Bob Anderson (Walter and Eliza Hall Institute, AU) *Pamela Bjorkman (Caltech, USA) *Helen Blau (Stanford University, UA) *Jeffrey Bluestone (UCSF, USA) *Christopher Buckley (University of Oxford, UK) *Dennis Burton (Scripps Research Institute, USA) *Calliope Dendrou (University of Oxford, UK) *Peter Donnelly (University of Oxford, UK) *Kevan Herold (Yale University, USA) *Richard Hodes (NIH National Institute on Aging, USA) *Nebojsa Janjic (Somalogic, USA) *Yvonne Jones (University of Oxford, UK) *Luke Jostins-Dean (University of Oxford, UK) *Carl June (University of Pennsylvania, USA) (TBC) *Michael Karin (UCSD, USA) *Purvesh Khatri (Stanford University, USA) *Simon Leedham (University of Oxford) *Francis Lund (University of Alabama at Birmingham, USA) *Ira Mellman (Genentech, USA) *Michel Nussenzweig (Rockefeller University, USA) *Jeffrey Ravetch (Rockefeller University, USA) *Soumya Raychaudhuri (Harvard Medical School, USA) *Alexander Rudensky (Memorial Sloan Kettering Cancer Centre, USA) *Vladislav Sandler (HemoGenyx) *Owen Sansom (University of Glasgow, UK) *Lawrence Steinmam (Stanford University, USA) *Gitta Stockinger (Crick, UK) *Sarah Teichmann (Wellcome Sanger Institute, UK) *Craig Thompson (Memorial Sloan Kettering Cancer Centre, USA) (TBC) *Carola Vinuesa (ANU College of Health & Medicine, AU) *Georg Wick (Medizinische Universität Innsbruck, AT) KENNEDY INSTITUTE OF RHEUMATOLOGY From Laboratory to Clinic: Accelerating Experimental Medicine Approaches Tuesday, 04 September 2018 to Friday, 07 September 2018 Trinity College, Oxford From Laboratory to Clinic is an annual translational research conference established in 1984. It is organised by an international committee led by past and present Directors of the Kennedy Institute, Profs Sir Marc Feldmann, Sir Ravinder Maini and Fiona Powrie. The meeting brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. TOPICS * Artificial Intelligence * Immune Regulation * Genetics/Genomics * Inflammation, Repair and Cancer * B cells: Basic to Clinical * Experimental Medicine Continued..... Tullynessle3 Sep '18 - 20:33 - 495 of 539 Edit 0 0 0 Re Post 494 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191015 14:59:37